Hydroxycinamic acid for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Hydroxycinamic acid may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed hydroxycinamic acid in detail.
, Phytochemical Profiling and in Vitro Anti-Sars-Cov-2 Evaluation of Verbascum Zerdust: Integration of Ace2-Spike Inhibition Assay and Computational Approaches, Bitlis Eren University Journal of Science and Technology, doi:10.17678/beuscitech.1725713
Plants have long been used to protect and maintain human health. Due to the increasing costs and side effects of synthetic drugs, interest in herbal products is increasing day by day. For this reason, research continues in laboratories around the world to discover new drug active ingredients of natural origin. In the present study, the COVID-19 Spike ACE2 binding inhibition capacity of Verbascum zerdust Fırat was studied using commercial kits. In addition, the plant content was determined by HPLC-DAD analysis and the interaction of the components in the plant content with the 7U0N protein was determined by molecular docking analysis. In addition, the ADME profiles of the molecules detected in the plant content were determined using the SwissADME web tool. According to the results obtained, Verbascum zerdust showed the highest inhibition value at 0.001µl concentration (15.38%). In molecular docking analysis, catechin carbohydrate showed the highest binding affinity to the 7U0N complex (∆G= -8.3 kcal/mol). Among the molecules detected in the plant extract, catechin hydrate, resveretrol, quercetin and t-cinamic acid fully complied with the Lipinski, Ghose, Veber, Egan and Muegge criteria. In conclusion, the results obtained indicate that Verbascum zerdust plant can be used in the treatment of COVID-19.